- Home
- PHAR vs LEU Comparison
PHAR vs LEU Comparison
Compare PHAR & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- LEU
- Stock Information
- Founded
- PHAR 1988
- LEU 1998
- Country
- PHAR Netherlands
- LEU United States
- Employees
- PHAR N/A
- LEU N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- PHAR Health Care
- LEU Industrials
- Exchange
- PHAR Nasdaq
- LEU Nasdaq
- Market Cap
- PHAR 718.1M
- LEU 3.2B
- IPO Year
- PHAR N/A
- LEU 1998
- Fundamental
- Price
- PHAR $10.27
- LEU $175.90
- Analyst Decision
- PHAR Strong Buy
- LEU Buy
- Analyst Count
- PHAR 3
- LEU 9
- Target Price
- PHAR $30.00
- LEU $165.63
- AVG Volume (30 Days)
- PHAR 4.3K
- LEU 1.4M
- Earning Date
- PHAR 07-31-2025
- LEU 08-05-2025
- Dividend Yield
- PHAR N/A
- LEU N/A
- EPS Growth
- PHAR N/A
- LEU 40.85
- EPS
- PHAR N/A
- LEU 6.39
- Revenue
- PHAR $320,708,000.00
- LEU $471,400,000.00
- Revenue This Year
- PHAR $13.31
- LEU $3.22
- Revenue Next Year
- PHAR $7.68
- LEU $9.91
- P/E Ratio
- PHAR N/A
- LEU $27.47
- Revenue Growth
- PHAR 24.13
- LEU 58.72
- 52 Week Low
- PHAR $6.65
- LEU $33.51
- 52 Week High
- PHAR $12.61
- LEU $211.31
- Technical
- Relative Strength Index (RSI)
- PHAR 49.06
- LEU 60.56
- Support Level
- PHAR $10.46
- LEU $164.91
- Resistance Level
- PHAR $11.49
- LEU $184.43
- Average True Range (ATR)
- PHAR 0.34
- LEU 15.53
- MACD
- PHAR -0.12
- LEU -3.14
- Stochastic Oscillator
- PHAR 31.46
- LEU 38.54
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.